Filing Flows

Filing Flows › Companies › Bionano Genomics › Cash flow

Bionano Genomics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$4.7M in Q2 2026 · −$20.5M over twelve months

Operating cash flow−$4.7M
Free cash flow−$4.7M
Cash conversion cycle107 days

Analysis

In Q2 2026, Bionano Genomics generated −$4.7M of operating cash flow. That is $1.2M less than in Q2 2025 (−$3.5M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$20.5M; the largest uses were operating cash flow ($20.5M), net borrowing (+) / repaid (−) ($12.2M), other financing ($1.2M); besides operations, cash came from other investing ($18.5M), shares issued ($16.0M); the cash balance rose by $669K.

Operating cash flow was −$4.7M against net income of −$7.4M. The largest differences: depreciation & amortization +$2.3M, stock-based pay +$970K, accrued liabilities −$550K.

Its cash conversion cycle was 107 days (receivables 47 + inventory 173 − payables 114).

Free cash flow

Bionano Genomics: free cash flow by quarterBionano Genomics: free cash flow by quarter−$13.3MQ3 2024−$6.5MQ4 2024−$2.8MQ1 2025−$3.5MQ2 2025−$5.9MQ3 2025−$4.2MQ4 2025−$5.7MQ1 2026−$4.7MQ2 2026
Operating cash flow less capital spending.
Bionano Genomics: operating cash flow against capital spendingBionano Genomics: operating cash flow against capital spendingOperating cash flowCapital spending−$13.3M$0Q3 2024−$6.5M$0Q4 2024−$2.8M$0Q1 2025−$3.5M$0Q2 2025−$5.9M$0Q3 2025−$4.2M$0Q4 2025−$5.7M$0Q1 2026−$4.7M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$4.7M, Capital spending $0.

Capital allocation, year by year

Bionano Genomics: where the cash came from (up) and went (down), by fiscal yearBionano Genomics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsFY2021: Operating cash flow −$71.9MFY2021: Net borrowing −$15.0MFY2021: Shares issued $343MFY2021: Capital spending −$638K$343MFY2021FY2022: Operating cash flow −$125MFY2022: Net borrowing −$36KFY2022: Shares issued $23.1MFY2022: Asset sales $26KFY2022: Capital spending −$792KFY2022: Acquisitions −$31.3M$23.2MFY2022FY2023: Operating cash flow −$125MFY2023: Net borrowing $80.0MFY2023: Shares issued $57.7M$138MFY2023FY2024: Operating cash flow −$68.9MFY2024: Net borrowing $12.9MFY2024: Shares issued $44.4M$57.4MFY2024FY2025: Operating cash flow −$16.3MFY2025: Net borrowing −$4.9MFY2025: Shares issued $31.1M$31.1MFY2025
Over these 5 years operating cash flow totalled −$407M; the largest uses were operating cash flow ($407M) and acquisitions ($31.3M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$9.9M
Debtnone
Net cash$9.9M
Cash runway6 months

Bionano Genomics is burning cash: its operations consume cash, a free cash flow of −$20.5M a year at the current rate against $9.9M of cash and investments: a runway of about 6 months before any new financing.

Where the cash came from and went

Bionano Genomics: sources (+) and uses (−) of cash, Q2 2026Bionano Genomics: sources (+) and uses (−) of cash, Q2 2026Other investing$13.7MNet borrowing (+) / repaid (−)−$10.3MOperating cash flow−$4.7MCash drawn (+) / kept (−)$681KShares issued$620KOther financing−$26KExchange rates$1K
Bionano Genomics: sources (+) and uses (−) of cash, TTM to Q2 2026Bionano Genomics: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$20.5MOther investing$18.5MShares issued$16.0MNet borrowing (+) / repaid (−)−$12.2MOther financing−$1.2MCash drawn (+) / kept (−)−$669KExchange rates$28K

From profit to cash

Bionano Genomics: net income to operating cash flow, Q2 2026Bionano Genomics: net income to operating cash flow, Q2 2026Net income−$7.4MDepreciation & amortization$2.3MStock-based pay$970KReceivables−$233KInventory$77KPayables−$500KAccrued liabilities−$550KPrepaid and other assets−$26KOperating cash flow−$4.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202647173114107
Q1 202663203140127
Q4 202556164117103
Q3 202550216141125
Q2 202546304179171
Q1 202556316173199
Q4 202457286152191
Q3 20248812555157

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$4.7M−$10.3M$620K$681K−$4.7M
Q1 2026−$5.7M−$20K$705K−$403K−$5.7M
Q4 2025−$4.2M−$18K$1.8M−$1.4M−$4.2M
Q3 2025−$5.9M−$1.9M$12.9M$497K−$5.9M
Q2 2025−$3.5M−$1.5M$3.1M$63K−$3.5M
Q1 2025−$2.8M−$1.5M$13.3M$5.9M−$2.8M
Q4 2024−$6.5M−$2.0M$6.7M−$379K−$6.5M
Q3 2024−$13.3M−$1.6M$10.1M$12.6M−$13.3M

Bionano Genomics: income statement and cash flow

Bionano Genomics, Q2 2026: revenue $8.2M (+21% year over year), operating margin -88.3%. The chart follows the revenue to costs, profit and cash.

Bionano Genomics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.